We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
+49.77%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$161M
AUM Growth
+$22.9M
Cap. Flow
-$13.2M
Cap. Flow %
-8.22%
Top 10 Hldgs %
93.66%
Holding
18
New
1
Increased
–
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$4.09M

Top Sells

Rank Stock Value
1
CBAY
Cymabay Therapeutics
CBAY
+$10.9M
2
CASC
Cascadian Therapeutics, Inc.
CASC
+$3.42M
3
CRSP icon
CRISPR Therapeutics
CRSP
+$2.65M
4
EVAR
Lombard Medical, Inc.
EVAR
+$399K

Sector Composition

Rank Sector Weight
1 Healthcare 98.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.74B
$86.2M 53.59%
1,887,202
-64,157
-3% -$2.65M
SIEN
2
DELISTED
Sientra, Inc.
SIEN
$21.2M 13.19%
219,901
– –
PRTK
3
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$13.5M 8.41%
1,041,131
– –
ONCT
4
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$6.02M 3.74%
2,423
– –
OBSV
5
DELISTED
ObsEva SA Ordinary Shares
OBSV
$5.84M 3.63%
440,000
– –
TARA icon
6
Protara Therapeutics
TARA
$230M
$5.04M 3.14%
50,447
– –
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
$3.55M 2.21%
273,417
-873,660
-76% -$10.9M
CLLS
8
Cellectis
CLLS
$271M
$3.15M 1.96%
100,000
– –
CHMA
9
DELISTED
Chiasma, Inc. Common Stock
CHMA
$3.12M 1.94%
2,080,595
– –
SRRA
10
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$2.98M 1.85%
+36,111
New +$4.09M
ADAP
11
DELISTED
Adaptimmune Therapeutics
ADAP
$2.81M 1.74%
250,000
– –
OCGN icon
12
Ocugen
OCGN
$440M
$2.44M 1.52%
14,815
– –
RARE icon
13
Ultragenyx Pharmaceutical
RARE
$2.82B
$1.94M 1.21%
38,100
– –
AUPH icon
14
Aurinia Pharmaceuticals
AUPH
$2.01B
$1.31M 0.81%
252,129
– –
IMDZ
15
DELISTED
Immune Design Corp.
IMDZ
$1.15M 0.71%
352,300
– –
DERM
16
DELISTED
Dermira, Inc.
DERM
$559K 0.35%
70,000
– –
CASC
17
DELISTED
Cascadian Therapeutics, Inc.
CASC
– –
-925,000
Closed -$3.42M
EVAR
18
DELISTED
Lombard Medical, Inc.
EVAR
– –
-3,473,452
Closed -$399K

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q1 2018 Portfolio in Review

As of Q1 2018, Abingworth held 18 positions worth $161M, up 17% from $138M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

Abingworth withdrew a net $13.2M in Q1 2018, closing 2 positions and reducing 2 holdings. Its most notable exit was Cascadian Therapeutics, Inc., an estimated $3.42M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier.

Against the trend, Abingworth opened a new position in Sierra Oncology, Inc. Common Stock worth $2.98M.

  • Abingworth's largest Q1 2018 buy was Sierra Oncology, Inc. Common Stock: 36,111 shares worth $2.98M.
  • Abingworth's biggest Q1 2018 reduction was Cymabay Therapeutics, cutting an estimated $10.9M.
  • Abingworth fully exited Cascadian Therapeutics, Inc. in Q1 2018, selling an estimated $3.42M.
  • Abingworth's ten largest holdings make up 94% of its $161M portfolio in Q1 2018.
  • Abingworth opened 1 new position and closed 2 in Q1 2018.
  • Abingworth's portfolio value rose 17% quarter-over-quarter to $161M.

Based on Abingworth's 13F filing for Q1 2018, filed 15 May 2018.